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Objective
We characterized the ability of mometasone furoate/
formoterol (MF/F) combination to improve asthma
control in adults/adolescents inadequately controlled
on low-, medium-, and high-dose inhaled corticoster-
oids (ICS).
Methods
Changes from baseline to endpoint (last evaluable visit) in
Asthma Control Questionnaire (ACQ) scores were
assessed in subjects from 3 Phase III trials (low- [n=746],
medium- [n=781], and high-dose [n=728] previous ICS
use). The ACQ categorizes asthma symptoms and use of
rescue-medication using a 7-point scale (0=totally con-
trolled, 6=severely uncontrolled). In two placebo con-
trolled trials, subjects were randomized to receive MF/F
(100/10μgo r2 0 0 / 1 0 μg), MF (100μgo r2 0 0 μg ) ,F( 1 0 μg),
or placebo (26 weeks; all twice-daily [BID] via metered-
dose inhaler [MDI]); In a non-placebo controlled trial,
subjects were randomized to receive MF/F 200/10μg,
MF/F 400/10μg, or MF 400μg (12 weeks; all BID via MDI).
Results
Baseline ACQ scores (1.23–1.38 (MF/F 100/10μgs t u d y ) ,
1.41–1.47 (MF/F 200/10μg study), and 1.83–1.87 (MF/F
200/10 and 400/10μg study) indicated that subjects in all
trials were not well controlled (<0.75) on ICS monother-
apy. MF/F yielded ACQ improvements (100/10μg=–0.36;
200/10μg=–0.40) vs MF (100μg=–0.26; 200μg=–0.23),
and deteriorations with F 10μg (+0.07; +0.11) and pla-
cebo (+0.24; +0.14). MF/F 400/10μgi m p r o v e da s t h m a
control by –0.51 compared with –0.33 for MF 400μg
monotherapy. Improvements for MF/F at all doses
achieved minimal importance difference of ≥0.5 point
increase.
Conclusion
MF/F showed clinically important improvement in
asthma control at all strengths and was better than MF,
F and placebo.
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